Yüklüyor......
Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma
Chimeric antigen receptor (CAR)‐T cell therapy is now approved in the United States and Europe as a standard treatment for relapsed/refractory B‐cell malignancies. It has also been approved recently by the Therapeutic Goods Administration in Australia and may soon be publicly reimbursed. This advanc...
Kaydedildi:
| Yayımlandı: | Clin Transl Immunology |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6526894/ https://ncbi.nlm.nih.gov/pubmed/31139410 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cti2.1050 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|